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Allergic contact dermatitis is the second most commonly reported occupational illness, accounting for 10% to 15% of all
occupational diseases. This highlights the importance of developing rapid and sensitive methods for hazard identiﬁcation of
chemical sensitizers. The murine local lymph node assay (LLNA) was developed and validated for the identiﬁcation of low
molecular weight sensitizing chemicals. It provides several beneﬁts over other tests for sensitization because it provides a
quantitative endpoint, dose-responsive data, and allows for prediction of potency. However, there are also several concerns with
this assay including: levels of false positive responses, variability due to vehicle, and predictivity. This report serves as a concise
review which brieﬂy summarizes the progress, advances and limitations of the assayover the last decade.
1.Th eM urin eLocalL ym p hN odeA s s a y
Allergic disease continues to be an important environmental
and occupational health concern. Allergic contact dermatitis
(ACD) is the second most commonly reported occupational
illness, accountingfor10%to15%ofall occupationaldiseas-
es. This poses a signiﬁcant public health burden with com-
binedannual costsofupto$1billionformedicalcosts,work-
ers compensation, and lost time from work. This highlights
the importance of developing rapid and sensitive methods
for hazard identiﬁcation of chemical sensitizers. Historically,
guinea pig tests (GPT; i.e., the guinea pig maximization
(GPMT) and the Buehlerassay (BA)) were used for this pur-
pose. The human repeated insultp a t c ht e s t( H I R P T )i ss t i l l
used in many countries as a conﬁrmatory test for skin aller-
gens; however, ethical concerns and the existence of reliable
alternativetesting procedureshavelargely eliminated thejus-
tiﬁcation for the HIRPT [1]. The murine local lymph node
assay (LLNA) was developed in 1989 [2] and continues to
undergo reﬁnement as an alternative for the evaluation of
sensitizing potential of low molecular weight (LMW) chem-
icals. The LLNAhas beenevaluatedextensively in thecontext
ofbothnationalandinternationalinterlaboratorytrials. This
data has been reviewed and validated in the USA by the In-
teragency Coordinating Committee on the Validation of
Alternative Methods (ICCVAM) [3, 4]a n di nE u r o p eb yt h e
European Center for the Validation of Alternative Methods
(ECVAM) [5] resulting in the LLNA becoming the preferred
method for assessing skin sensitization potential by various
regulatory authorities [6, 7]. In 2002, the LLNA was adopted
by the Organization for Economic Co-operation and De-
velopment (OECD) as a standalone method (OECD 429).
Recently the LLNA has been designated as the initial re-
quirement for sensitization testing with the new registration,
evaluation, authorization and restriction of chemical sub-
stances (REACH) regulation in the European Union.
The basic principle underlying the traditional LLNA is
that chemical sensitizers induce a primary proliferation (in-
duction phase) of lymphocytes in the lymph nodes draining
thesiteofchemicalapplicationwhichcanbequantiﬁedusing
measurement of radiolabeled thymidine incorporation into
thelymphnodecellularDNA.Lowmolecularweight(LMW)
chemical sensitizers, referred to as haptens (or prohaptens),
are themselves too small to be allergenic and must bind to
a protein to be allergenic. Three major cells types, kerati-
nocytes, Langerhans cells, and T-lymphocytes, have been
identiﬁed as central in the induction phase of ACD. The
role of keratinocytes in both the induction and elicitation2 Journal of Allergy
phases has been recently reviewed [8]. Haptens can directly
stimulate keratinocytes present in the epidermis of the skin
to release inﬂammatory mediators such as interleukins 1, 6
and 18, granulocyte-macrophage colony-stimulating factor,
and tumor necrosis factor-α. The chemokine CCL2, which
can recruit dendritic cells into the site of inﬂammation, is
also upregulated in keratinocytesfollowing hapten exposure.
Langerhans cells (LCs), immature dendritic cells (DCs)
presentwithin theepidermis,takeupandprocesshaptenated
protein within the major histocompatibility complex (MHC
II). In the presence of the proper cytokine-signaling milieu,
LCsmigrate from theskin through the aﬀerentlymphatics to
lymph nodes draining the site of contactand become mature
DCs during that process. DCs then present the haptenated
peptide to responsive T-lymphocytes [9, 10]. Activated T-
lymphocytes divide and diﬀerentiate into both T-eﬀector
and T-memory cells which starts the central phase of sen-
sitization [11], and it is this allergen-driven proliferation re-
sponse that is quantiﬁed in the LLNA.
In the performance of the LLNA (based on the original
guidelines), mice (female CBA/Ca or CBA/J preferred strain;
minimum offour pergroup) are topicallyexposed to accept-
ed vehicle, increasing concentrations (minimum of three) of
LMW chemical, or accepted positive control on the dorsal
surface of each ear once a day for three consecutive days.
On day 6, mice are injected, intravenously, via the lateral tail
vein with 3H-thymidine (3H-T). Five hours later, following
sacriﬁce of the left and right draining auricular lymph nodes
located at the bifurcation of the jugular vein are excised and
pooled for each animal. Lymphocyte proliferation, deter-
mined by quantiﬁcation ofradioactive (3H-T) incorporation
in the draining lymph nodes, is evaluated using a liquid
scintillation analyzer. A chemical is classiﬁed as a sensitizer
if at one or more test concentration it induces a three-fold
or greater increase in draining lymph node cell proliferation
compared with concurrent vehicle-treated control mice and
data follows dose-response kinetics. The data generated
from the LLNA has been demonstrated to provide a simple
means of obtaining an objective, quantitative evaluation of
sensitization. From the analysis generated during the review
process, the LLNA was determined to be 86% accurate (N =
97), 82% speciﬁc (N = 33), 87% sensitive (N = 93) with
positive predictivity of 93% (N = 87) when compared
to GPT [4]. More detailed descriptions of the LLNA are
reported elsewhere [4, 12].
2.BeneﬁtsoverPreviouslyUsed Assaysfor
SkinSensitization
There are many advantages to the LLNA in comparison to
GPT (OECD test guideline 406, [13]. The LLNA provides a
quantitative endpoint, dose-responsive data, allows for pre-
diction of potency (EC3; eﬀective concentration for a SI of 3
inproliferationoflymph nodecells) anddoesnotrequirethe
use of an adjuvant. GPT, which evaluate the elicitation phase
of skin sensitization provide a qualitative endpoint which
tendstobehighlyvariableinpart duetoitssubjectivenature,
and these tests are not typically used for estimations of po-
tency. Evaluation of the sensitization phase as an endpoint
results in a reduced time for animals to be on study and
eliminatesthediscomfortassociatedwiththedevelopmentof
inﬂammation in the elicitation phase of the response. Com-
pared to GPT, the LLNA reduces animal numbers needed,
improves animal welfare, and decreases experimental time
andcosts.Thisreport isnotintendedasanexhaustiveupdate
on the progress of the LLNA, but rather a concise review
which will brieﬂy summarize the progress, advances, and
limitations of the assay over the last decade.
3.Th eP o t e n ti alU s eo fth eLLN Ai n
RiskAssessment
Although the LLNA was originally validated for the purpose
of hazard identiﬁcation, much attention and debate have
been recently focused on the potential use of the LLNA in
human quantitative risk assessment [14]. Risk assessment is
generallyviewed asafour-step process: hazard identiﬁcation,
dose-response assessment, exposure assessment, and risk
characterization. The LLNA provides information for use in
theﬁrst twosteps.Lymphocyteproliferationhasbeenproven
to be related both causally and quantitatively to chemical
sensitization. Potency estimation can therefore be made by
comparing the concentration of chemicals necessary for the
acquisition of sensitization. The EC3, eﬀective chemical con-
centration required for a SI = 3, can be mathematically de-
rived by linear interpolation of dose-response data [15]. The
EC3 value has been shown to be highly reproducible, con-
sistent among laboratories and stable over time [16–18].
While the EC3 value, is not a measure of absolute po-ten-
cy which can be directly extrapolated to humans, it is an
objectivemeasureofrelativeallergenicpotencyofonepoten-
tial sensitizer with that of another [19]. In 2003, after exten-
sive laboratory investigations, four categorizes of chemical
sensitization potency, with 10-fold diﬀerence in EC3 value
(extreme (<0.1%), strong (≥0.1–<1.0%), moderate (≥1.0–
<10%), and weak (≥10%)), were determined by the ECE-
TOC (European Center for Ecotoxicology and Toxicology of
Chemicals) [20]. Recently, these classiﬁcation schemes for
regulatory purposes have been reevaluated by ICCVAM and
the European Chemical Bureau, and their ﬁndings will be
released later this year [14].
The results from numerous studies support the use of
the LLNA in quantitative risk assessment by demonstrating
an overall association between EC3 and relative potency of
chemical allergens in humans [21–25]. EC3 values of 26
chemicals were found to have a linear relationship with the
threshold for the induction of sensitization derived from
humanrepeated insultpatchtest[21].Fromtheanalysisgen-
erated during its review process, the accuracy of the LLNA
versus human tests (human maximization test and human
patch test allergen) was 72% (N = 74) while the positive
predictivity was 96% (N = 51) [4].
There are concerns about extrapolating data generated
from the LLNA for potential use in risk assessment. The
LLNA is based on the induction phase of the hypersensitivity
response following acute (3 consecutive days) exposure.Journal of Allergy 3
The complexity of the induction-elicitation response and
the degree to which skin sensitization inﬂuences the dose of
chemical necessary to elicit a reaction are important factors
to consider. Theoretically, elicitation thresholds are lower
than those required for induction. Furthermore, the dose re-
quiredforinductionmaybedependentondurationfrequen-
cy and site of exposure. Human chemical exposure may be
the result of an incidental single contact, repeated exposure,
or continual exposure. These types of scenarios can present
diﬃculties when trying to classify weak (high EC3) versus
strong (low EC3) sensitizers. In general, chemicals with
high EC3 are considered to be of low risk to human while
chemicals with a low EC3 value present a much higher risk.
While this scenario usually holds true, there are other factors
that need to be considered such as: is there a greater risk for
allergy when there is frequent exposure to a weak sensitizer
versus infrequent exposure to a strong or extreme sensitizer?
Forexample, studies have found that although methyl meth-
acrylate is a weak sensitizer (EC3 value of 60–90%), numer-
ous cases of skin sensitization have been reported in individ-
uals exposed to plastic materials [26]. This ﬁnding could be
relatedtofactorssuchasdurationofexposure,exposure con-
centration, and route of exposure. In occupational settings,
workers have a greater potential for exposure to pure, undi-
luted chemicals than the general public which would most
likely be exposed to a diluted version in a consumer product.
While attempts are being made to use data generated from
LLNA studies toward utilization in risk assessment, all of
these factors need to be carefully considered.
4.LimitationsoftheLLNA
From the analysis generated during its review process, the
accuracy of the LLNA versus GPMT/BA was 89% (N = 97),
LLNA versus all GPT was 86% (N = 126), the LLNA versus
human data was 72% (N = 74), GPMT/BA versus human
was 72% (N = 57), and all guinea pig tests (GPT) versus
human’s was 73% (N = 62) [4]. In terms of accuracy,
sensitivity, speciﬁcity, and positive and negative predictivity,
the performance of the LLNA was found to be similar to
that of the GPMT/BA. Equally important, the performance
of the LLNA and the GPMT/BA was similar when each
assay was compared to human data. Nopredictive toxicology
tests will ever be 100% accurate, and because of this, it is
important to understand the limitations of each assay [27].
Inconsistencies between LLNA and human patch test data
have been documented [28]. While the mouse has been
identiﬁed as the optimal experimental model for the LLNA,
rodents have been shown to have increased skin penetration
of chemicals compared to humans [29, 30]. These types of
interspecies diﬀerencesmay contributeto some ofthe incon-
sistenciesbetweenanimal andhumanskinsensitization tests,
therefore,confoundinginterpretationoftheresultsespecially
with respect to potency determination. This section will
brieﬂy describe some of the limitations that have been
identiﬁed for the LLNA.
4.1. Level of False Positives. Irritants and sensitizers can both
induce lymphocyte proliferation. While sensitizers generate
antigen-speciﬁc lymphocyte proliferation, this response is
nonspeciﬁc for irritants. The use of 3H-T incorporation for
measurements oflymphocyteproliferation in theLLNAdoes
not allow for diﬀerentiation of the two. Forthis reason, it has
long been debated that the LLNA may give an unacceptable
number of false positives when nonsensitizing irritating
chemicals are tested [17, 31]. The determination of an SI
value of 3 as indicative of skin sensitization potential was
made after extensive evaluations of chemical datasets. It is a
threshold set as a precautionary measure to try and account
for background ﬂuctuations in lymphocyte proliferation
[15]. For example, topical application of the well-studied
surfactant sodium lauryl sulfate (SLS) has been shown to test
positive in the LLNA with SI values above the threshold limit
(3-fold increase) [9, 17, 31–34]. In contrast to the scenario
presented for SLS, when numerous nonsensitizing skin
irritants were evaluated using the LLNA, the majority tested
negative [35]. However, positive responses, occasionally
conﬂicting with data generated from other studies, to other
nonsensitizing irritants have been reported and include:
chloroform/methanol, Triton X-100, oxalic acid, methyl
salicylate, and nonanoic acid [34, 36]. Similar to SLS, the SI
valuesobtainedforthesecompoundsin theLLNAwere most
often low and close to the threshold level. More recently,
7/9 nonsensitizing irritating compounds (oleic acid, linoleic
acid, linolenic acid, undecylenic acid, maleic acid, squalene,
and octinol) tested positive in the LLNA with the highest SI
value of each substance between the range of 4.4–16.1 [37].
It is important to point out that these types of limitations
are not unique to the LLNA and have also been associated
with GPT for skin sensitization [38]a sw e l la sw i t hh u m a n
patch test studies [39].
Numerous methods have been developed based on the
mechanisms underlying the induction of sensitization to
try and distinguish between sensitizing and irritating com-
pounds. These include but are not limited to: measurements
of antigen expression on Langerhans cells [40], cytokine
production[41–43],DCactivation[44],andlymphnodecell
phenotyping[45–48].Atthistime,thesemodiﬁcationsofthe
standard LLNA are intended for use as research tools and are
not validated for the purpose of hazard identiﬁcation.
4.2. Variability due to Vehicle. Lymphocyte proliferation
has also been shown to be inﬂuenced by several factors
including vehicle selection [49]. OECD recommended vehi-
cles include: acetone/olive oil (AOO: 4:1v/v), dimethylfor-
mamide, methyl ethyl ketone, propylene glycol, dimethyl
sulphoxide,anddimethylsulfoxide(DMSO).Severalofthese
vehicles including AOO, DMSO, and propylene glycol have
been shown to augment the LLNA response of certain
chemicals. For example, AOO has been shown to give highly
variable results when used as a vehicle in the LLNA [50, 51].
In addition, research suggests that olive oil itself may cause
contact allergy [52, 53]. DMSO is a polar solvent that is
known as a penetration enhancer and may augment bioa-
vailability of the allergen across the stratum cornea. Another
commonly used LLNA vehicle propylene glycol has been
shown to suppress the proliferative eﬀects of certain chem-
icals such as 2,4-dinitrochlorobenzene (DNCB) [54]. Select4 Journal of Allergy
vehicles with the ability to enhance or suppress proliferative
responses may be an important consideration for weak
sensitizers with high EC3 values. Jowsey et al. [55]r e p o r t e d
that solvent selection was very important when conducting
the LLNA. They tested 15 diﬀerent solvents with multiple
allergens and found that when propylene glycol was used as
thevehicle,theEC3 obtained forthechemicals varied by >10
fold compared to the other vehicles used. This is consistent
with our study ofbromoalkanes [56].An approximate3-fold
diﬀerence in lymph node cell stimulation for C18 and C19
bromoalkanes was observed when dissolved in AOO versus
butanol/tetrahydrofuran (1/1). In addition, the importance
of other physical/chemical considerations for solvent selec-
tion and the potential inﬂuences on test results were noted.
While allergens may be soluble in AOO, the acetone quickly
volatilizes away during application of allergen to the skin.
Test compounds such as bromohexane may be lost due to
volatility,while thelongerchain bromoalkanes result in large
particulate-olive oil slurries that are poorly retained on the
skin with application in AOO. However, while these are
important factors to considerer, the degree of augmentation
duetovehicleselectionhasnottypicallybeenshown toaﬀect
the category of sensitization because the SI value is based on
increase in lymphocyte proliferation over vehicle control.
4.3. Inability to Distinguish Speciﬁc Type of Hypersensitivity
Response. There are two types of chemical allergy which
are of greatest relevance for occupational and consumer
exposures: skin sensitization causing allergic contact der-
matitis (Th1-typeimmune response) andsensitization of the
respiratory tract associated with allergic rhinitis and asthma
(Th2-immune response). In addition to identifying contact
sensitizers, it is generally accepted that LMW respiratory
sensitizers also test positive in the LLNA because the initial
sensitization or induction phase of allergy is similar for both
types of allergic responses [57]. Based on this concept, a
LMW chemical testing negative in the LLNAcan be classiﬁed
as nonsensitizing for urticarial, contact, and respiratory
allergies. However, there are currently no validated methods
to distinguish between these two types. Modiﬁcations of the
L L N Ah a v eb e e nd e v e l o p e dt ot r ya n dc l a s s i f yt h et y p eo f
chemical sensitizer. These include but are not limited to
methods that evaluate serum IgE levels (representative of a
Th2-type immune response) [57], cytokine ﬁngerprinting
(analysis of Th1 versus Th2 cytokines) [58–60], the mouse
ear swelling test (MEST) [61], and immune cell phenotyping
[48, 62].
Although there is mounting evidence that lymphocyte
proliferation can be used to identify contact and respiratory
allergens, dermal application is the only route of exposure
validated for the LLNA. While there is signiﬁcant evidence
suggesting that dermal exposure to sensitizers such as the
isocyanates and acid anhydrides can induce respiratory tract
sensitization [63–65], there are currently no validated test
methods to identify compounds, including high molecular
weight protein allergens that cannot pass through the skin.
Attempts are currently being made to address these issues
and will be discussed in greater detail later in this paper.
5.What IsinStorefortheFuture?
5.1. Updated OECD Guidelines. The OECD Guidelines for
the testing of chemicals are periodically reviewed as a re-
sult of nominations of new methods highlighting scientiﬁc
progress,changingregulatoryneeds,andanimalwelfare con-
siderations. Many modiﬁcations to the OECD guidelines
have been recently published [66] and will be brieﬂy de-
scribed in this section.
5.2. Nonradioactive Alternatives. Two modiﬁcations of the
LLNA to utilize nonradioactive endpoints have been devel-
oped. Advantages of these assays include the elimination of
occupational exposure to radioactivity and issues related to
radioactive waste. The LLNA: DA and LLNA: BrdU have
recently been reviewed, validated, and recommended by an
international peer review panel as useful for identifying
skin sensitizing and non-sensitizing substances, with certain
limitations [66] .T h e s em e t h o d sa r ec o n s i d e r e dt ob eo f
equal merit to the standard LLNA and may be employed
as an alternative to GPT or the standard LLNA. Positive or
negative results no longer require additional conﬁrmation.
As with all the validated tests discussed, both positive and
negative (solvent) controls must be run in parallel to the
test substance. The concept for the LLNA: BrdU method
(OECD 429B) is similar to that of the standard LLNA and is
based on the incorporation and quantiﬁcation of BrdU into
proliferating cells in the auricular lymph nodes following
topical chemical exposure [67]. BrdU incorporation is
measured byperoxidase-labeledBrdU-speciﬁcantibody.Fol-
lowing addition of a substrate, reaction with the peroxidase
produces a colored product that is quantiﬁed at a speciﬁc
absorbance using a microtiter plate reader. A chemical is
considered a sensitizer if an SI value ≥1.6 is obtained.
The second approved nonradioactive method is the
LLNA: DA (OECD 442A). The LLNA: DA (developed by
Daicel Chemical Industries, Ltd.) uses quantiﬁcation of
adenosine triphosphate (ATP) content (known to correlate
with living cell number) measured using bioluminescence as
an indicator of increased lymphocyte proliferation [68]. The
method utilizes the luciferase enzyme to catalyze the forma-
tionoflightfrom ATP andluciferin,which ismeasured using
a luminometer and linearly related to the ATP concentration
[66]. A chemical is considered a sensitizer if an SI value ≥1.8
is obtained. Although both of these assays provide quanti-
tative data suitable for dose-response assessment, the results
may not be directly compared to the EC3 values obtained for
the LLNA. The thresholds to determine sensitization (SI) for
these assays are lower than that established for the standard
LLNA,andSIvaluesforequivalentdosesofallergenalsotend
to be lower. It has not been established, to our knowledge,
if this shift in basal and allergen-induced SIs will provide
comparable EC3 determinations to the traditional LLNA. As
with any assay, there are limitations to these modiﬁcations.
Certain chemicals, such as ones that aﬀect ATP levels, have
been determined to be inappropriate for use with these types
of assay. In addition, ATP is very labile and the assay, as
presently validated, requires immediate analysis after sample
recovery.Journal of Allergy 5
5.3.Reduced LLNA. The reducedLLNA(rLLNA)isavalidat-
ed and accepted modiﬁcation to the standard LLNA which
was purposed in an eﬀort to reduce experimental animal use
fortheassessment ofskinsensitization potentialofchemicals
as well as toaddress thedemand for increases in sensitization
testing of chemicals required by REACH[66].This alteration
of the original protocol requires only a single, high-concen-
tration test group (the highest dose that does not produce
signiﬁcant irritation) and a positive control group [69, 70].
When used totest a substance for thepotential tocause aller-
gic contact dermatitis, the rLLNA uses fewer animals than
the LLNA to provide a “yes-no” result. ICCVAM has recom-
mended that the rLLNA be used routinely to determine the
allergic contact dermatitis hazard potential of chemicals and
productsbeforeconductingthemultidoseLLNAincasesthat
do not require dose-response information. Since the rLLNA
uses only a negative control group and a high-dose group,
use of the rLLNA can reduce the number of animals needed
for each test by 40% compared to the multidose LLNA.
Clear justiﬁcation and scientific rationale must be provided
before utilization of this method because it cannot generate
dose-response or potency data that could be used for risk
assessment.
5.4. Testing of Formulations. The standard LLNA was not
originally evaluatedforthetesting offormulations. However,
ICCVAMrecentlyrecommended, duetoa nomination by the
US Consumer Product Safety Commission, to reevaluate the
LLNA applicability domain. This would allow the LLNA to
be used to test any chemical or product, including pesticide
formulations, metals, substances in aqueous solutions, and
other products such as natural complex substances and dyes
unless the chemical or product to be tested has properties
thatmayinterfere withtheabilityoftheLLNAtodetectskin-
sensitizing substances [71]. This conclusion was based on
the compilation of data from previously described research
as well as newly generated data obtained for the purpose
of this evaluation. For immunotoxicological evaluation of
investigational new drugs, the FDA requires that “when a
murine LLNA is conducted to support the safety of clinical
trials, the sensitizing potential of the drug substance, clinical
excipient, and clinical formulation should be evaluated”
[72]. This modiﬁcation expanded the use and application of
theLLNAtotestformulationsfoundin occupationalsettings
and consumer products as well as individual chemicals.
5.5. Nonanimal Alternatives to the Standard LLNA. Much
focus has been placed on the use of in vitro, in chemico,a n d
in silico alternatives due to the increasing public and political
concerns regarding the use of animals in research. The
successful development, evaluation, and validation of these
nonanimal alternatives for evaluation of skin sensitization
willdependheavilyontheprecisionandaccuracywithwhich
theycanpredict the in vivo classiﬁcation of sensitizing chem-
i c a l .T h e ym u s tb ea b l et op r e d i c tt h ec o m p l e xi n t e r a c t i o n
of the chemical with all aspects of the immune response.
Numerousmethodsarebeingdevelopedforthispurposeand
arebasedonspeciﬁcmechanistic stepsthatoccurduringskin
sensitization including but not limited to: protein/peptide
binding and haptenization, activation of keratinocytes and
DC, and T-cell proliferation [73].
An u m b e ro fin silico methods currently exist and aim
to predict a novel chemical reactivity based on the known
in vivo reactivity of existing structurally similar chemicals.
This kind of theoretical computer modeling is referred to as
structural activity relationship (SAR) or quantitative struc-
tural activity relationship (QSAR). Derek for Windows and
TOPKAT are examples that have been used for several years.
This type of predictive tool allows the user to input a chemi-
cal structure and obtain a readout of the chemical constructs
that could potentially lead to sensitization [74]. Challenges
with this type of modeling include the analysis of chemicals
requiring metabolic activation. Although these models may
be helpful as an initial screen, inconsistent results have been
observed when compared to animal models of sensitization
[75, 76].
Computer and skin models are also being developed to
evaluate chemical epidermal bioavailability based on physi-
cal/chemical data [77]. A chemical must react with host pro-
teins to produce an altered or haptenated selfprotein before
sensitization can occur [78–80]. Additionally, some chemi-
cals termed prohaptens require metabolic or chemical con-
version before they can react with a protein. Eﬀorts have
alsofocusedoninvestigating whethertheintrinsic sensitizing
potentialofachemicalcan bepredictedfrom itselectrophilic
reactivity [81]. The direct peptide reactivity assay (DPRA)
investigates peptide reactivity kinetics to evaluate sensitiza-
tion and is currently undergoing validation by ECVAM. It
aims to model protein haptenation in chemico,b ym e a s u r i n g
the depletion of two synthetic peptides which are typical
reaction targets [82].
There are numerous in vitro tools being developed for
prediction of skin sensitizers. Several are based on critical
steps in chemical sensitization including keratinocyte and
DC activation [73, 77]. These pivotal points of sensitization
result in numerous cellular and molecular processes related
to antigen processing and presentation which can be evalu-
atedandmeasured.Theseincludeupregulationofcostimula-
tory molecules(CD83,CD86,CD40,and CD80)and various
cytokines(IL-1β,I L - 8 ,T NF - α,andIL-10)which canbemea-
sured by methods such as ﬂow cytometry and quantitative
real-time PT-PCR. Models are being developed using LC-
like dendritic cells derived from human bone marrow, cord
blood, or peripheral blood precursors [83, 84]a sw e l la s
DC-like cell lines including THP1 [84, 85], U937 [86], KG-
1[ 87, 88] and MUTZ-3 [89]. Limitations with these types
of protocols include: donor-to-donor variability (blood-
derivedDC-),complexity,expense,andlab-to-labvariability.
Two in vitro test methods, myeloid U973 skin sensiti-
zation test (MUSST) and human cell line activation test
(h-CLAT) have been evaluated and accepted for prevali-
dation as alternatives for evaluating skin sensitization [77]
by ECVAM. Limited success has also been obtained when
antigen-proliferative responses by na¨ ıve T-lymphocytes have
been evaluated in vitro following coincubation with chemi-
cal sensitizer-treated DCs or LCs [90–92]. These types of6 Journal of Allergy
assays have been able to identify strong but not weak sen-
sitizers.
It is anticipated that in the next several years a multipa-
rameter system will be available as a nonanimal alternative
for the prediction of skin sensitization. Increased conﬁdence
fora method would be based on inclusionofanalysis ofmul-
tiple phases of chemical sensitization.
5.6. Modiﬁcations of the LLNA to Identify Respiratory Aller-
gens. Giventhatpositiveresults canbeobtainedin theLLNA
for contact and respiratory allergens [57], numerous in vitro
and animal models have been investigated to diﬀerentiate
these responses. However, none are widely applied or fully
accepted, most probably due to the complexity of the system
and lack of validation eﬀorts [93, 94]. Respiratory allergens
are deﬁned by their ability to provoke a Th2-type immune
response. While a negative result in the LLNA typically ex-
cludes a LMW chemical as a respiratory sensitizer, there
is currently no validated screening for the identiﬁcation of
chemicals or proteins that result in allergic sensitization of
therespiratorytract.Numerousmethodsandendpointshave
beenpurposedfortheidentiﬁcationofrespiratory sensitizers
and will brieﬂy be described here.
It has long been debated which is the best route of expo-
sure when investigating respiratory sensitizers. Although
topical application of select strong respiratory sensitizers
has been shown to result in sensitization of the respiratory
tract, [63–65] this does not hold true for all LMW chemical
sensitizers or high molecular weight protein allergens that
cannot pass through the skin. Alternative routes of sensi-
tization including intranasal, intratracheal, oropharyngeal,
and intradermal have been examined to try and address this
issue [95–97]. However, there are several disadvantages with
these routes of exposure including chemical solubility (most
are not water-soluble), vehicle selection, species variability,
requirements for sophisticated equipment and expense have
made this a diﬃcult task [57]. These complexities have
prevented a general consensus on the best exposure route for
evaluation of respiratory sensitizers.
Several endpoints have been examined to try and dis-
tinguish respiratory sensitizers from contact sensitizers and
are typically based on diﬀerences between Th1-(allergic al-
veolitis/hypersensitivity pneumonitis) and Th2-immune re-
sponse (allergic asthma and/or rhinitis) [57]. These include
the analysis of total serum IgE levels and cytokine ﬁnger
printing [98–100]. While IgE levels tend to be a hallmark
of respiratory sensitization and allergic asthma, they do not
always correlate to clinical manifestation of asthma [101–
103]. This may be due to antigen speciﬁcity or failure of
the detection of antigen-speciﬁc IgE. Identiﬁcation of respir-
atory allergen has also been attempted through cytokine
proﬁling. Respiratory allergens generally induce increases in
the Th2 cytokines, IL-4, IL-5, IL-10, and IL-13, while contact
allergens have been associated with increases in the Th1
cytokines, INF-γ and TNF-α [58, 104]. This differentiation
is not absolute as some respiratory sensitizers have also
been shown to increase INF-γ [105]. Other asthma mod-
els examine lung function along with histopathology, fol-
lowing dermal sensitization and respiratory challenge, for
the evaluation of respiratory sensitization [106, 107]. The
above-mentioned factors along with method variability have
complicated the development of a standardized assay for the
identiﬁcation of respiratory sensitizers. Similar to the LLNA,
limitations with these types of models have also been iden-
tiﬁed and include false positives associated with exposure to
respiratory irritants and diﬃculties with potency measure-
ments [57].
6.Conclusions
In conclusion, it should be restated that no toxicologypre-
dictive test is perfect, and each will always require a balance
between sensitivity and speciﬁcity. The LLNA has been
recognized as a gold standard for hazard identiﬁcation of
LMWsensitizerforthelastdecade,andmostoftheidentiﬁed
limitationsarenotuniquetotheLLNAitselfbutrathertothe
use of an animal model. Many modiﬁcations to the original
LLNA OECD guidelines have been published, and others
are currently being developed. Among the biggest challenges
ahead are maintaining predictive value while moving from
whole animal to in vitro systems.
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